European Lung Cancer Congress

Camrelizumab Combo Doubles 5-Year Survival in Phase 3 Lung Cancer Trial

April 2nd 2025, 4:35pm

Article

Camrelizumab combo doubled the five-year survival rate in advanced squamous lung cancer, reducing mortality risk by 43%, in a Phase 3 trial.

Tagrisso May Improve Survival in Advanced EGFR-Mutant NSCLC

April 1st 2025, 1:13pm

Article

Tagrisso is associated with positive outcomes among patients with unresectable stage 3 EGFR-mutant non-small cell lung cancer.

COCOON Trial Regimen Reduces Dermatologic Side Effects in Mutated Lung Cancer

March 31st 2025, 8:00pm

Article

The COCOON trial regimen reduced dermatologic side effects in patients with EGFR-mutant non-small cell lung cancer, phase 2 trial data showed.

First-line Rybrevant Combo Extends Survival in Advanced Lung Cancer

March 31st 2025, 7:00pm

Article

First-line Rybrevant plus Lazcluze significantly extended overall survival versus Tagrisso in mutated, advanced or metastatic non-small cell lung cancer.